Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Ovarian Cancer

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

• Similarities and differences between germline and somatic genetic mutations
• Incidence and clinical significance of BRCA mutations and other germline or somatic alterations (eg, PALB2, ATM, RAD51C/D) in ovarian cancer
• Current roles of next-generation sequencing and germline sequencing for advanced ovarian cancer; similarities and differences among available genetic testing platforms
• Purpose and potential benefits of genetic counseling after a diagnosis of ovarian cancer

MODULE 2: Role of PARP Inhibitors for Advanced Ovarian Cancer

• Mechanism of antitumor activity of PARP inhibitors, and rationale for their use as maintenance therapy for patients with newly diagnosed advanced ovarian cancer
• Long-term findings from Phase III studies with olaparib, olaparib/bevacizumab and niraparib maintenance for newly diagnosed ovarian cancer
• Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab or niraparib maintenance
• Current clinical utility, if any, of PARP inhibitors for relapsed/refractory ovarian cancer, including among patients who have experienced disease progression on or after prior PARP inhibitor therapy

MODULE 3: Side Effects and Other Practical Considerations with PARP Inhibitors

• Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
• Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with ovarian cancer
• Optimal monitoring and management paradigms for common PARP inhibitor-related toxicities
• Long-term risk of acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
• Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

MODULE 4: Current and Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment

• Frequency of and scientific rationale for targeting folate receptor alpha (FRα) in ovarian cancer
• Mechanism of action and structural components of mirvetuximab soravtansine
• Published research findings with mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer
• FDA approval of mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer; implications for biomarker assessment and current management
• Early findings with mirvetuximab soravtansine for FRα-high, platinum-sensitive advanced ovarian cancer; ongoing evaluation and potential utility in this setting

MODULE 5: Toxicities Associated with Mirvetuximab Soravtansine

• Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
• Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
• Importance of collaboration with eye care specialists for patients receiving mirvetuximab soravtansine
• Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

MODULE 6: Other Approved and Investigational Antibody-Drug Conjugates for Ovarian Cancer

• Frequency of HER2 expression in advanced ovarian cancer; optimal timing of and approach to testing
• FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for ovarian cancer management
• Biological rationale for targeting CDH6 for ovarian cancer; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
• Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced ovarian cancer

MODULE 7: Current Role of Relacorilant for Advanced OC

• Incidence and clinical relevance of glucocorticoid receptor (GR) overexpression in ovarian cancer
• Mechanism of action of the selective GR modulator relacorilant; rationale for combining relacorilant with chemotherapy for advanced ovarian cancer
• Published efficacy and safety findings with relacorilant in combination with nab paclitaxel versus nab paclitaxel alone for platinum-resistant advanced ovarian cancer
• Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant advanced ovarian cancer, and integration into current clinical algorithms

MODULE 8: Tolerability Considerations with Relacorilant/Nab Paclitaxel

• Rationale for nab paclitaxel as a therapeutic partner for relacorilant; necessity of avoiding corticosteroid use with relacorilant
• Tolerability profile of relacorilant/nab paclitaxel in published clinical trials; relative contributions of each agent in terms of toxicities
• Incidence and severity of cytopenias with relacorilant/nab paclitaxel; appropriate monitoring and management
• Rates of and strategies to manage peripheral neuropathy with relacorilant/nab paclitaxel

MODULE 9: Utility of Immune Checkpoint Inhibition for Advanced OC

• Historical outcomes documented with anti-PD-1/PD-L1 antibodies as monotherapy for advanced ovarian cancer; potential explanations for the lack of activity with these agents for ovarian cancer relative to other tumor types
• Emerging data demonstrating a progression-free survival advantage with the addition of pembrolizumab to chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer
• Impact of PD-L1 expression on overall survival in the aforementioned emerging data set; potential implications for biomarker analysis for advanced ovarian cancer
• Potential clinical role of pembrolizumab for platinum-resistant recurrent ovarian cancer

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and counsel appropriate individuals regarding personalized treatment recommendations.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
• Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
• Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
• Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
• Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
• Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR — Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.